Important note: Information in this article was accurate in November 2009. The state of the art may have changed since the publication date.
Visceral adipose tissue returns to baseline after stopping therapeutic intervention with rHGH
HIV Treat Bull - 2009 Nov/Dec;10(11/12): 09
Simon Collins, HIV i-Base
Central fat accumulation remains one of the most distressing but least understood metabolic complications, with very limited management options. Several studies have reported that recombinant Human Growth Hormone (rHGH) can reduce central visceral adipose tissue (VAT), although earliest studies at higher doses (4-6 mg/day) were associated with significant toxicity.
Additionally, any benefit seemed dependent on maintaining treatment, and the optimal dose remained to be established. It was important to see the 3-years results from a study from the Massachusetts General Hospital, presented by Steven Grinspoon, carried out in people with reduced growth hormone (GH) secretion (peak GH <7.5 ng/mL).[1] This was a randomised double-blind study of low dose rHGH (an average dose of 0.33 mg/day: starting at 2 mcg/kg/day but increasing to 6 mcg/kg/day, titrating to the upper quartile of normal IGF-1 range). After 18 months patients crossed over to either active drug or placebo, depending on their original randomisation. The 18 month initial results have already been published.[2]
Pooled analysis for both arms showed that 18 months treatment significantly reduced mean (+SD) VAT compared to placebo (-7.3 ±21.3% vs +4.8 ±22.7%, p<0.0001) and trunk fat (-3.2 ±15.3% vs +2.4 ±13.1%, p=0.003). rHGH also had a statistically positive effect on reducing systolic and diastolic blood pressure, triglycerides and LDL-cholesterol and increasing lower limb fat, but had a negative glyceamic affect: increasing fasting glucose and 2-hour glucose on OGTT (see Table 1). No impact for seen for intima-media thickness, though this was not elevated at basline.
During the crossover period, the benefits of rHGH on VAT reversed to baseline within 6 months. The increase in IFG-1 seen during 18 month treatment (approximately +100ng/mL increase from baseline) also dropped within 2-4 weeks of discontinuation.
| Table 1: Pooled effect of rHGH vs placebo at 18 months (mean%, ±SD) | |||
| rHGH | Placebo | p | |
| VAT | -7.3±21.3% | +4.8±22.7% | <0.0001 |
| Trunk fat | -3.2±15.3% | +2.4±13.1% | 0.003 |
| Lower limb fat | +4.9±13.3% | +1.1±11.8 | 0.03 |
| Systolic BP | -2.0±13.9% | +2.6±12.0% | 0.007 |
| Diastolic BP | -1.1±13.7% | +5.8±17.1% | 0.0009 |
| Triglycerides | -0.9±43.4% | +11.0±52.9% | 0.05 |
| LDL-chol | -2.7±23.7% | +4.9±28.7% | 0.03 |
| Fasting glucose | 6.7±11.7% | 2.5±11.4% | 0.007 |
| 2-hour glucose | 16.5±48.6% | 0.1±26.9% | 0.002 |
Comment
The importance of continuing treatment in order to maintain any reduction in VAT has also been reported with tesamorelin, which although has reduced toxicity, appears to reverse benefits back to baseline VAT levels if discontinued. An FDA decision on approval of tesamorelin is expected in the second quarter of 2010.
References
Janet Lo, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation. JAMA. 2008 Aug 6;300(5):509-19. [Full-text]
2009-11-10
IB2009-11-09
©2009. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in November 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.